Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.41 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 6/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.34 |
| ▸ | KDM4A | O75164 | 4/20 | 0.34 |
| ▸ | KDM3A | Q9Y4C1 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 3/20 | 0.33 |
| ▸ | KDM6B | O15054 | 5/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 5/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24958915 | 0.81 | KDM5C (0.38) | IRAK4KDM5CKDM4CKDM4AKDM3A | |
| SCHEMBL24958695 | 0.81 | DPP4 (0.37) | IRAK4METDPP4 | |
| SCHEMBL24958704 | 0.80 | PIM1 (0.54) | IRAK4PIM1JAK2METNTRK1 | |
| SCHEMBL24958866 | 0.74 | BRD4 (0.40) | IRAK4JAK2METDPP4NTRK1 | |
| SCHEMBL24958864 | 0.74 | BRD4 (0.40) | IRAK4JAK2METDPP4NTRK1 | |
| SCHEMBL24958697 | 0.71 | LGALS3 (0.38) | IRAK4KCNJ5METDPP4 | |
| SCHEMBL24958717 | 0.69 | CHRNB2 (0.39) | METDPP4 | |
| SCHEMBL24958943 | 0.69 | IRAK4 (0.49) | IRAK4KCNJ5PIM1JAK2MET | |
| SCHEMBL19762908 | 0.69 | CYP2C19 (0.43) | IRAK4NTRK1 | |
| SCHEMBL24958703 | 0.68 | NTRK1 (0.41) | IRAK4PIM1JAK2METNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | IRAK4 995/4885KCNJ5 903/4885KDM5C 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.